Search research articles
Contact Us
Filters
Showing results (61-70 of 140) with videos related to
Page
of 14
Sort By:
International Journal of Cancer
|
August 14, 2012
Distinct tumor protein p53 mutants in breast cancer subgroups
Anne Dumay, Jean-Paul Feugeas, Evelyne Wittmer, et al.
Molecular Cancer Therapeutics
|
May 20, 2016
Chromatin Regulators as a Guide for Cancer Treatment Choice
Zachary A Gurard-Levin, Laurence O W Wilson, Vera Pancaldi, et al.
Breast Cancer Research : BCR
|
July 30, 2009
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment
Marc A Bollet, Alexia Savignoni, Leanne De Koning, et al.
Plos One
|
April 25, 2012
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma
Fabien Reyal, Marc A Bollet, Martial Caly, et al.
Breast Cancer Research : BCR
|
September 15, 2020
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy
Luc Cabel, Dan Rosenblum, Florence Lerebours, et al.
Plos One
|
December 20, 2015
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
Hélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Plos One
|
August 31, 2019
Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation
Alice Clément-Zhao, Marie-Laure Tanguy, Paul Cottu, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 22, 2023
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab
Romain-David Seban, Emilie Arnaud, Delphine Loirat, et al.
Plos One
|
September 1, 2012
Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
Maura Campitelli, Emmanuelle Jeannot, Martine Peter, et al.
Breast Cancer (Tokyo, Japan)
|
April 10, 2024
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases
Alexandre De Moura, Delphine Loirat, Sarah Vaillant, et al.
Page
of 14
Search research articles
Search
Showing results (61-70 of 140) with videos related to
Sort By:
Page
of 14
International Journal of Cancer
|
August 14, 2012
Distinct tumor protein p53 mutants in breast cancer subgroups
Anne Dumay, Jean-Paul Feugeas, Evelyne Wittmer, et al.
Molecular Cancer Therapeutics
|
May 20, 2016
Chromatin Regulators as a Guide for Cancer Treatment Choice
Zachary A Gurard-Levin, Laurence O W Wilson, Vera Pancaldi, et al.
Breast Cancer Research : BCR
|
July 30, 2009
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment
Marc A Bollet, Alexia Savignoni, Leanne De Koning, et al.
Plos One
|
April 25, 2012
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma
Fabien Reyal, Marc A Bollet, Martial Caly, et al.
Breast Cancer Research : BCR
|
September 15, 2020
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy
Luc Cabel, Dan Rosenblum, Florence Lerebours, et al.
Plos One
|
December 20, 2015
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
Hélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Plos One
|
August 31, 2019
Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation
Alice Clément-Zhao, Marie-Laure Tanguy, Paul Cottu, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 22, 2023
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab
Romain-David Seban, Emilie Arnaud, Delphine Loirat, et al.
Plos One
|
September 1, 2012
Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
Maura Campitelli, Emmanuelle Jeannot, Martine Peter, et al.
Breast Cancer (Tokyo, Japan)
|
April 10, 2024
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases
Alexandre De Moura, Delphine Loirat, Sarah Vaillant, et al.
Page
of 14